RE:RE:RE:Melanoma sample provides bit of an answerMost here are just trying to uncover and discusss the facts so we can handicap the situation in front of shareholders, and now with a far more tilted view given the pre-clinical vs. clinical experience with this drug molecule. I certainly glossed over the success statistics on cancer drugs in phase 1 seeing all the safety data. So hurdles are much higher now on monotherapy.
At least there's now 2 or 3 other aspects around sort1 they may be able to push at the same time if they are clever --the PD-L1 data for a partner wanting to differentiate and possibly muiltiply their immuno-oncology drug to leap-frog competition, someone in the carboplatin area looking to do the same with that combo data, and someone to run with the anti-metastatic aspect with the pre/post treatment combo data. Each could be hived off and partnered if they hustle, and I"m sure they've ranked them on which is most likely and will just push that first, but you never know once you get out there and talk to industry people in N.Am for the first time. I noticed someone from a Nordic pharma read their post on linkedin or whereever that was. We know there's a bunch of folks in Sweden that know all about what sort1 targeting could do with cancer stem cells. They just need one deal to put credibility into what they're doing and add value back in to the program.
Anyway, hopefully this board returns to trying to uncover facts, comparables, valuation exercises, fair critiques of management decisions, key Board and Mgmt folks etc.. and stating your opinion of events based on those facts. All that's fair game for investment analysis. All the name-calling and silly statements about law enforcement, beliefs, etc.. is totally counter-productive and deserves blocking so it can be ignored as useless babble.